JP2015187156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015187156A5 JP2015187156A5 JP2015125342A JP2015125342A JP2015187156A5 JP 2015187156 A5 JP2015187156 A5 JP 2015187156A5 JP 2015125342 A JP2015125342 A JP 2015125342A JP 2015125342 A JP2015125342 A JP 2015125342A JP 2015187156 A5 JP2015187156 A5 JP 2015187156A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- medicament according
- administered
- medicament
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38084202P | 2002-05-17 | 2002-05-17 | |
| US60/380,842 | 2002-05-17 | ||
| US42460002P | 2002-11-06 | 2002-11-06 | |
| US60/424,600 | 2002-11-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009116367A Division JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017095838A Division JP2017132817A (ja) | 2002-05-17 | 2017-05-12 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015187156A JP2015187156A (ja) | 2015-10-29 |
| JP2015187156A5 true JP2015187156A5 (cg-RX-API-DMAC10.html) | 2016-02-04 |
| JP6194335B2 JP6194335B2 (ja) | 2017-09-06 |
Family
ID=29553516
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505051A Pending JP2005530784A (ja) | 2002-05-17 | 2003-05-16 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2006288966A Pending JP2007008966A (ja) | 2002-05-17 | 2006-10-24 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116367A Expired - Lifetime JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116363A Withdrawn JP2009191072A (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2012273326A Expired - Lifetime JP5830005B2 (ja) | 2002-05-17 | 2012-12-14 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2013038222A Withdrawn JP2013126999A (ja) | 2002-05-17 | 2013-02-28 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2015125342A Expired - Lifetime JP6194335B2 (ja) | 2002-05-17 | 2015-06-23 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2017095838A Pending JP2017132817A (ja) | 2002-05-17 | 2017-05-12 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505051A Pending JP2005530784A (ja) | 2002-05-17 | 2003-05-16 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2006288966A Pending JP2007008966A (ja) | 2002-05-17 | 2006-10-24 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116367A Expired - Lifetime JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116363A Withdrawn JP2009191072A (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2012273326A Expired - Lifetime JP5830005B2 (ja) | 2002-05-17 | 2012-12-14 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2013038222A Withdrawn JP2013126999A (ja) | 2002-05-17 | 2013-02-28 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017095838A Pending JP2017132817A (ja) | 2002-05-17 | 2017-05-12 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Country Status (19)
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| DE60234585D1 (cg-RX-API-DMAC10.html) | 2001-02-27 | 2010-01-14 | Us Government | |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CN1981761B (zh) | 2002-05-17 | 2011-10-12 | 细胞基因公司 | 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物 |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| JP2006508950A (ja) * | 2002-10-31 | 2006-03-16 | セルジーン・コーポレーション | 黄斑変性の治療用組成物 |
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| WO2005016326A2 (en) * | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2005028436A2 (en) | 2003-09-17 | 2005-03-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
| US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| JP5089170B2 (ja) * | 2003-12-02 | 2012-12-05 | セルジーン コーポレイション | 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物 |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| JP2007529434A (ja) | 2004-03-17 | 2007-10-25 | ラース マイケル ラーセン， | 視覚サイクルの阻害による網膜症の予防 |
| EP1737453A4 (en) * | 2004-03-22 | 2008-11-26 | Celgene Corp | METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS |
| AU2004319758A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| CA2586950A1 (en) * | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| CA2588597A1 (en) * | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| ES2359162T3 (es) * | 2005-09-01 | 2011-05-19 | Celgene Corporation | Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas. |
| WO2007072225A2 (en) * | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| AU2007238785B2 (en) | 2006-04-13 | 2013-02-07 | Agnieszka Ambrozak | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
| RU2426542C2 (ru) * | 2006-05-26 | 2011-08-20 | Селджин Корпорейшн | Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| MX2009001441A (es) * | 2006-08-07 | 2009-07-06 | Facet Biotech Corp | Metodos para tratar mieloma multiple usando terapias de combinacion basadas en anticuerpos anti-cs1. |
| AP2009004834A0 (en) * | 2006-10-19 | 2009-04-30 | Celgene Corp | Methods and compositions using immunomodulatory c ompounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases |
| RU2348420C2 (ru) * | 2007-04-17 | 2009-03-10 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ лечения местно-распространенного рака легкого |
| KR20230065354A (ko) * | 2007-09-28 | 2023-05-11 | 셀룰래리티 인코포레이티드 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
| UA104579C2 (uk) * | 2007-12-10 | 2014-02-25 | Байокрист Фармасьютикалз, Инк. | Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом |
| CA2712724A1 (en) * | 2008-01-29 | 2009-08-06 | Celgene Corporation | Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency |
| RU2398525C1 (ru) * | 2009-03-25 | 2010-09-10 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ лечения рака легкого |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| CA2780998C (en) * | 2009-11-24 | 2016-07-12 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
| EP4289838A3 (en) | 2010-02-11 | 2024-03-13 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2011224166B2 (en) * | 2010-03-12 | 2014-08-21 | Celgene Corporation | Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| KR20190017065A (ko) * | 2010-08-18 | 2019-02-19 | 테레사 데이셔 | 림프양 조직에 줄기 세포와 조상 세포 결합을 저해하고, 그리고 림프 조직에서 배 중심을 재생하기 위한 조성물과 방법 |
| WO2012062366A1 (en) * | 2010-11-11 | 2012-05-18 | Ingo Schmidt-Wolf | Compositions comprising wnt inhibitors for treating cancer |
| US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
| US9694015B2 (en) * | 2012-09-10 | 2017-07-04 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| SG11201507759WA (en) * | 2013-04-02 | 2015-10-29 | Celgene Corp | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| CN104231068A (zh) * | 2014-01-27 | 2014-12-24 | 苏州发士达生物科技有限公司 | 人白细胞介素ii突变体及其应用 |
| JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
| US10034872B2 (en) | 2014-08-22 | 2018-07-31 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| DK3198035T3 (da) | 2014-09-26 | 2023-01-30 | Allarity Therapeutics Europe ApS | Fremgangsmåder til forudsigelse af medicinrespons |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| CN107249502A (zh) * | 2015-01-20 | 2017-10-13 | 斯里瓦特桑·拉加万 | 自照明式面颊牵开器 |
| US11000536B2 (en) | 2015-04-30 | 2021-05-11 | Nant Holdings Ip, Llc | Patient treatment via teratogenic pharmaceutical compounds |
| HRP20211478T1 (hr) * | 2015-06-29 | 2021-12-24 | Bristol-Myers Squibb Company | Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka |
| CA3002381A1 (en) * | 2015-10-21 | 2017-04-27 | Teclison Limited | Compositions and methods for immune-mediated cancer therapy |
| CN105388237B (zh) * | 2015-12-28 | 2017-02-01 | 成都百裕金阁莱药业有限公司 | 阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法 |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| MX2019011679A (es) | 2017-04-01 | 2019-11-01 | Avm Biotechnology Llc | Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular. |
| EA201992765A1 (ru) | 2017-05-24 | 2020-03-25 | Новартис Аг | Белки на основе антител с привитым цитокином и способы их применения в лечении рака |
| RU2020110236A (ru) * | 2017-10-26 | 2021-11-26 | Синбиас Фарма АГ | Состав леналидомида с немедленным высвобождением |
| EA202092248A1 (ru) | 2018-04-23 | 2021-02-04 | Селджин Корпорейшн | Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими |
| JP7495886B2 (ja) * | 2018-05-23 | 2024-06-05 | セルジーン コーポレイション | 多発性骨髄腫を治療すること及び４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルのバイオマーカーの使用 |
| JP7098825B2 (ja) * | 2018-09-07 | 2022-07-11 | メッドシャイン ディスカバリー インコーポレイテッド | 三環式置換ピペリジンジオン類化合物 |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021067546A1 (en) * | 2019-10-04 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof |
| MX2022004688A (es) * | 2019-10-21 | 2022-05-10 | Celgene Corp | Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona. |
| DK4048278T3 (da) * | 2019-10-21 | 2024-01-08 | Celgene Corp | Fremgangsmåder til behandling af hæmatologiske maligniteter under anvendelse af 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluor-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindolin-1,3-dion |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3228601A (en) | 1964-02-20 | 1966-01-11 | Monarch Marking Systems Inc | Controls for marking machine |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| DE69739802D1 (de) | 1996-07-24 | 2010-04-22 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels |
| EP1361210B1 (en) | 1996-08-12 | 2008-12-24 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| ES2313154T3 (es) * | 1996-11-05 | 2009-03-01 | The Children's Medical Center Corporation | Composiciones que comprenden talodimina y dexametasona para el tratamiento de cancer. |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| DK1169021T3 (da) * | 1999-04-01 | 2010-01-11 | Hana Biosciences Inc | Sammensætninger og fremgangsmåder til behandling af lymfom |
| CN1429121A (zh) * | 2000-03-17 | 2003-07-09 | 细胞治疗公司 | 聚谷氨酸－喜树碱结合物及其制备方法 |
| KR100790589B1 (ko) * | 2000-05-15 | 2008-01-02 | 셀겐코포레이션 | 암 치료용 조성물 및 치료 방법 |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| PT1353672E (pt) | 2000-11-30 | 2008-01-11 | Childrens Medical Center | Síntese da 4-amino talidomida enantiómeros |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| CN1981761B (zh) * | 2002-05-17 | 2011-10-12 | 细胞基因公司 | 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物 |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
-
2003
- 2003-05-16 CN CN2006101504843A patent/CN1981761B/zh not_active Expired - Fee Related
- 2003-05-16 EP EP03728969A patent/EP1505973B1/en not_active Revoked
- 2003-05-16 CA CA2752127A patent/CA2752127A1/en not_active Abandoned
- 2003-05-16 ES ES03728969T patent/ES2340027T3/es not_active Expired - Lifetime
- 2003-05-16 DK DK03728969.1T patent/DK1505973T3/da active
- 2003-05-16 CN CN2011102571780A patent/CN102429908A/zh active Pending
- 2003-05-16 NZ NZ549175A patent/NZ549175A/en not_active IP Right Cessation
- 2003-05-16 AT AT03728969T patent/ATE459357T1/de active
- 2003-05-16 CA CA2727824A patent/CA2727824A1/en not_active Abandoned
- 2003-05-16 EP EP09004756A patent/EP2087891A3/en not_active Withdrawn
- 2003-05-16 CN CN201310344594.3A patent/CN103393681B/zh not_active Expired - Lifetime
- 2003-05-16 IL IL16525403A patent/IL165254A0/xx unknown
- 2003-05-16 EP EP10177041A patent/EP2272512A1/en not_active Withdrawn
- 2003-05-16 WO PCT/US2003/015470 patent/WO2003097052A2/en not_active Ceased
- 2003-05-16 MX MXPA04011311A patent/MXPA04011311A/es active IP Right Grant
- 2003-05-16 CA CA2752140A patent/CA2752140A1/en not_active Abandoned
- 2003-05-16 CA CA2794060A patent/CA2794060C/en not_active Expired - Lifetime
- 2003-05-16 EP EP10177056A patent/EP2272513A1/en not_active Withdrawn
- 2003-05-16 CA CA2727830A patent/CA2727830C/en not_active Expired - Lifetime
- 2003-05-16 EP EP09008775A patent/EP2105136A3/en not_active Withdrawn
- 2003-05-16 DE DE60331537T patent/DE60331537D1/de not_active Expired - Lifetime
- 2003-05-16 CN CN201110256752.0A patent/CN102379874B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP10185504A patent/EP2316455A1/en not_active Withdrawn
- 2003-05-16 CA CA2794297A patent/CA2794297A1/en not_active Abandoned
- 2003-05-16 EP EP14189022.8A patent/EP2915533B1/en not_active Revoked
- 2003-05-16 CN CN201410690665.XA patent/CN104606193A/zh not_active Withdrawn
- 2003-05-16 KR KR1020067020849A patent/KR100822149B1/ko not_active Expired - Fee Related
- 2003-05-16 JP JP2004505051A patent/JP2005530784A/ja active Pending
- 2003-05-16 EP EP09008756.0A patent/EP2105135B1/en not_active Revoked
- 2003-05-16 CN CN2011102561581A patent/CN102335173A/zh active Pending
- 2003-05-16 NZ NZ563281A patent/NZ563281A/en not_active IP Right Cessation
- 2003-05-16 NZ NZ572388A patent/NZ572388A/en not_active IP Right Cessation
- 2003-05-16 CA CA2752124A patent/CA2752124A1/en not_active Abandoned
- 2003-05-16 PT PT03728969T patent/PT1505973E/pt unknown
- 2003-05-16 NZ NZ536907A patent/NZ536907A/en not_active IP Right Cessation
- 2003-05-16 CN CN2011102566053A patent/CN102302494A/zh active Pending
- 2003-05-16 ES ES09008756.0T patent/ES2521672T3/es not_active Expired - Lifetime
- 2003-05-16 CA CA2672000A patent/CA2672000C/en not_active Expired - Lifetime
- 2003-05-16 CN CN201310343756.1A patent/CN103495169B/zh not_active Expired - Lifetime
- 2003-05-16 NZ NZ584663A patent/NZ584663A/en not_active IP Right Cessation
- 2003-05-16 AU AU2003234626A patent/AU2003234626B2/en not_active Expired
- 2003-05-16 CN CN2013103449770A patent/CN103393695A/zh not_active Withdrawn
- 2003-05-16 CA CA2476983A patent/CA2476983C/en not_active Expired - Lifetime
- 2003-05-16 CN CN201110257161.5A patent/CN102342938B/zh not_active Expired - Lifetime
- 2003-05-16 SI SI200331793T patent/SI1505973T1/sl unknown
- 2003-05-16 CN CN038168995A patent/CN1697655B/zh not_active Expired - Lifetime
- 2003-05-16 CN CN201310344609.6A patent/CN103494817A/zh not_active Withdrawn
- 2003-05-16 EP EP12158938.6A patent/EP2561874A3/en not_active Withdrawn
- 2003-05-16 PT PT90087560T patent/PT2105135E/pt unknown
- 2003-05-16 CA CA2752122A patent/CA2752122A1/en not_active Abandoned
- 2003-05-16 KR KR1020047018587A patent/KR100793564B1/ko not_active Expired - Lifetime
- 2003-11-06 CN CNA2003801083980A patent/CN1735415A/zh active Pending
- 2003-11-06 ZA ZA200503656A patent/ZA200503656B/xx unknown
-
2004
- 2004-11-16 IL IL165254A patent/IL165254A/en active IP Right Grant
- 2004-11-22 ZA ZA200409388A patent/ZA200409388B/xx unknown
- 2004-11-22 ZA ZA200409387A patent/ZA200409387B/en unknown
-
2006
- 2006-10-19 IL IL178745A patent/IL178745A/en active Protection Beyond IP Right Term
- 2006-10-19 IL IL178747A patent/IL178747A/en active IP Right Grant
- 2006-10-19 IL IL178748A patent/IL178748A/en active IP Right Grant
- 2006-10-19 IL IL178746A patent/IL178746A0/en unknown
- 2006-10-24 JP JP2006288966A patent/JP2007008966A/ja active Pending
-
2009
- 2009-05-13 JP JP2009116367A patent/JP5839770B2/ja not_active Expired - Lifetime
- 2009-05-13 JP JP2009116363A patent/JP2009191072A/ja not_active Withdrawn
- 2009-05-26 IL IL198978A patent/IL198978A/en active IP Right Grant
-
2010
- 2010-04-23 CY CY20101100363T patent/CY1110013T1/el unknown
-
2012
- 2012-05-10 IL IL219732A patent/IL219732A0/en unknown
- 2012-12-14 JP JP2012273326A patent/JP5830005B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-28 JP JP2013038222A patent/JP2013126999A/ja not_active Withdrawn
-
2014
- 2014-11-27 CY CY20141100987T patent/CY1115782T1/el unknown
-
2015
- 2015-01-27 LU LU92642C patent/LU92642I2/xx unknown
- 2015-02-06 CY CY2015003C patent/CY2015003I2/el unknown
- 2015-06-23 JP JP2015125342A patent/JP6194335B2/ja not_active Expired - Lifetime
-
2016
- 2016-03-22 IL IL244727A patent/IL244727A0/en unknown
-
2017
- 2017-05-12 JP JP2017095838A patent/JP2017132817A/ja active Pending